国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (1): 53-56.doi: 10.3760/cma.j.issn.1673-422X.2017.01.014

• 综述 • 上一篇    下一篇

肺癌驱动基因及其靶向治疗药物

黄炎,杨继元   

  1. 434000 荆州，长江大学附属第一医院肿瘤科
  • 出版日期:2017-01-08 发布日期:2016-12-07
  • 通讯作者: 杨继元，Email: yangjiyuanchina@163.com E-mail:yangjiyuanchina@163.com

Driver genes and targeted drugs in lung cancer

Huang Yan, Yang Jiyuan   

  1. Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou 434000, China
  • Online:2017-01-08 Published:2016-12-07
  • Contact: Yang Jiyuan, Email: yangjiyuanchina@163.com E-mail:yangjiyuanchina@163.com

PDF

2565

被引次数

4

摘要： 随着肿瘤分子生物学的发展，针对肺癌驱动基因的分子靶向治疗已成为晚期肺癌不可或缺的一部分。目前最成功的例子就是针对表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）的靶向治疗。现在越来越多的肺癌驱动基因突变已被发现，包括ROS1基因融合、成纤维细胞生长因子1扩增、KRAS、BRAF和PIK3CA基因突变等。明确这些基因突变的频率及临床意义，对指导肺癌的临床治疗有着重要的意义。

关键词: 肺肿瘤, 驱动基因, 靶向治疗

Abstract: With the development of molecular biology of cancer, molecular targeted therapy which targeted the driver genes in lung cancer has become an inevitable part of the treatment of advanced lung cancer. The most successful examples of targeted therapy are targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). More and more driver genes have been discovered, including ROS1 gene fusion, fibroblast growth factor receptor 1 amplification, KRAS, BRAF, PIK3CA gene mutation and so on. It is meaningful for guiding the treatment of lung cancer that defines the mutation incidence and clinical significance of driver genes in lung cancer.

Key words: Lung neoplasms, Driver genes, Targeted therapy